The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Silver47 Exploration
AGA:CC
Purpose Bitcoin ETF
BTCC:CA
Fidelity Advantage Bitcoin ETF
FBTC:CC
Black Swan Graphene
SWAN:CC
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
Aug. 29, 2018 09:39AM PST
Biotech InvestingProMIS Neurosciences (TSX:PMN) has announced it has issued a narrated overview of its second quarter 2018 foperational results. “We continued to make significant progress on three main priorities in the second quarter of 2018”, stated ProMIS Executive Chairman, Eugene Williams. “First, to maintain PMN310 on track for clinical trial start in the second half of 2019 …
ProMIS Neurosciences (TSX:PMN) has announced it has issued a narrated overview of its second quarter 2018 foperational results.
“We continued to make significant progress on three main priorities in the second quarter of 2018”, stated ProMIS Executive Chairman, Eugene Williams. “First, to maintain PMN310 on track for clinical trial start in the second half of 2019 with initiation of cell line development supporting product manufacturing; second, to differentiate the oligomer selectivity of PMN310 as best in class profile for the treatment of Alzheimer’s disease (AD) versus other, less selective amyloid-beta (Ab) directed therapies in development; and third, to expand our portfolio by developing therapeutic antibodies targeting toxic oligomers of alpha-synuclein for Parkinson’s disease (PD) and toxic aggregates of Tar-DNA binding protein (TDP43) for ALS, with a view to partnering these assets.”
The narrated overview can be found on the ProMIS Neurosciences website by clicking on the link below:
https://bit.ly/2wsr8Op
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.